Literature DB >> 10537061

Tissue transglutaminase is increased in Huntington's disease brain.

M Lesort1, W Chun, G V Johnson, R J Ferrante.   

Abstract

The polyglutamine-expanded N-terminal region of mutant huntingtin causes neurodegeneration in Huntington's disease (HD). Neuronal intranuclear and cytosolic inclusions composed of mutant huntingtin are found in brains of HD patients. Because tissue transglutaminase cross-links proteins into filamentous aggregates and polypeptide-bound glutamines are primary determining factors for tissue transglutaminase-catalyzed reactions, it has been hypothesized that tissue transglutaminase may contribute to the formation of these aggregates. In this report immunohistochemical and biochemical methods were used to demonstrate that tissue transglutaminase expression and transglutaminase activity are elevated in HD brains in a grade-dependent manner. In the striatum, tissue transglutaminase activity was significantly increased in the grade 3 HD cases compared with controls. When normalized to the neuronal marker calbindin D28k, immunoblot analysis revealed that in the striatum the levels of tissue transglutaminase were significantly increased in all HD cases compared with controls. Immunohistochemical staining of the HD striatum revealed that tissue transglutaminase immunoreactivity was markedly increased in all grades as compared with controls. In the superior frontal cortex, tissue transglutaminase activity was significantly higher in all HD cases as compared with controls. Quantitative analysis of immunoblots demonstrated that tissue transglutaminase levels were elevated in HD grades 2 and 3 cases. Tissue transglutaminase immunoreactivity within the superior frontal neocortex was also greater in all the HD cases compared with controls. These data clearly indicate that tissue transglutaminase is elevated in HD brain and may play a role in the disease process.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10537061

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  40 in total

1.  Therapeutic effects of cystamine in a murine model of Huntington's disease.

Authors:  Alpaslan Dedeoglu; James K Kubilus; Thomas M Jeitner; Samantha A Matson; Misha Bogdanov; Neil W Kowall; Wayne R Matson; Arthur J L Cooper; Rajiv R Ratan; M Flint Beal; Steven M Hersch; Robert J Ferrante
Journal:  J Neurosci       Date:  2002-10-15       Impact factor: 6.167

2.  Transglutaminase 2 protects against ischemic stroke.

Authors:  A J Filiano; J Tucholski; P J Dolan; G Colak; G V W Johnson
Journal:  Neurobiol Dis       Date:  2010-05-06       Impact factor: 5.996

Review 3.  γ-Glutamylamines and neurodegenerative diseases.

Authors:  Thomas M Jeitner; Kevin Battaile; Arthur J L Cooper
Journal:  Amino Acids       Date:  2012-03-10       Impact factor: 3.520

4.  Structural characterization of transglutaminase-catalyzed cross-linking between glyceraldehyde 3-phosphate dehydrogenase and polyglutamine repeats.

Authors:  Margherita Ruoppolo; Stefania Orrù; Simona Francese; Ivana Caputo; Carla Esposito
Journal:  Protein Sci       Date:  2003-01       Impact factor: 6.725

Review 5.  Transglutaminase 2: a molecular Swiss army knife.

Authors:  Soner Gundemir; Gozde Colak; Janusz Tucholski; Gail V W Johnson
Journal:  Biochim Biophys Acta       Date:  2011-10-10

6.  Two isoforms of tissue transglutaminase mediate opposing cellular fates.

Authors:  Marc A Antonyak; Jaclyn M Jansen; Allison M Miller; Thi K Ly; Makoto Endo; Richard A Cerione
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-20       Impact factor: 11.205

7.  Increased levels of gamma-glutamylamines in Huntington disease CSF.

Authors:  Thomas M Jeitner; Wayne R Matson; John E Folk; John P Blass; Arthur J L Cooper
Journal:  J Neurochem       Date:  2008-07-01       Impact factor: 5.372

8.  Striatal expression of a calmodulin fragment improved motor function, weight loss, and neuropathology in the R6/2 mouse model of Huntington's disease.

Authors:  Ying Dai; Nichole L Dudek; Qian Li; Stephen C Fowler; Nancy A Muma
Journal:  J Neurosci       Date:  2009-09-16       Impact factor: 6.167

Review 9.  Aggregation of expanded huntingtin in the brains of patients with Huntington disease.

Authors:  Guylaine Hoffner; Sylvie Souès; Philippe Djian
Journal:  Prion       Date:  2007 Jan-Mar       Impact factor: 3.931

10.  Tissue transglutaminase-induced aggregation of alpha-synuclein: Implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies.

Authors:  Eunsung Junn; Ruben D Ronchetti; Martha M Quezado; Soo-Youl Kim; M Maral Mouradian
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-07       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.